Categories: NewsPharmaceutical

Glaukos to Release Third Quarter 2023 Financial Results after Market Close on November 1, 2023

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Conference Call and Webcast Scheduled for 1:30 p.m. PT

ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release third quarter 2023 financial results after the market close on Wednesday, November 1, 2023. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on November 1, 2023.

A link to the live webcast will be available on the company’s website at http://investors.glaukos.com. To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (International) and enter Conference ID 7935742. A replay will be archived on the company’s website following completion of the call.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and continues to develop a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases.

Contacts

Chris Lewis

Vice President, Investor Relations and Corporate Affairs

(949) 481-0510

clewis@glaukos.com

Staff

Recent Posts

Phillips Medisize Launches TheraVolt Medical Connectors to Support Next-Gen Device Integration, Connectivity and Performance

Designed to address increasing demand for advanced medical connectors in growing specialties such as electrophysiology…

37 minutes ago

Phillips Medisize Launches TheraVolt Medical Connectors to Support Next-Gen Device Integration, Connectivity and Performance

Designed to address increasing demand for advanced medical connectors in growing specialties such as electrophysiology…

38 minutes ago

ForeSee Medical and Vim Announce Strategic Partnership to Enhance Risk Adjustment and Streamline Provider Workflows

SAN DIEGO--(BUSINESS WIRE)--ForeSee Medical Inc., a leading AI-powered risk adjustment software company, and Vim, a…

38 minutes ago

ForeSee Medical and Vim Announce Strategic Partnership to Enhance Risk Adjustment and Streamline Provider Workflows

SAN DIEGO--(BUSINESS WIRE)--ForeSee Medical Inc., a leading AI-powered risk adjustment software company, and Vim, a…

40 minutes ago

Butterfly Network’s RoHS Lead Exemption Revocation Request Progresses to Stakeholder and Consultant Assessment

Oeko-Institut appointed for third-party evaluation; stakeholder consultation will run June 6, 2025 - August 1,…

41 minutes ago

Ambio Life Sciences Launches World’s First Clinical Ibogaine Program for Patients With Neurodegenerative Conditions

Facilities and care team tailored for patients with complex medical needs Specialized protocol includes optimized…

42 minutes ago